NASDAQ · ELYM
Healthcare · Biotechnology
$5.11
Down-$0.05 (-0.97%)
Updated Aug 28, 2026, 5:18 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ELYM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ELYM.
ELYM research
Company profile and research snapshot.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 8, 2023 | HC Wainwright & Co. | Neutral | — |
| Feb 10, 2023 | HC Wainwright & Co. | Neutral | — |
| Oct 28, 2022 | HC Wainwright & Co. | Buy | — |
| Aug 16, 2022 | SVB Leerink | Outperform | — |
| Jul 11, 2022 | SVB Leerink | Outperform | — |
No generated briefing is available yet.
defenseworld.net · Dec 5, 2025
Eliem Therapeutics, Inc. (NASDAQ: ELYM - Get Free Report) shares shot up 6.1% during trading on Thursday. The stock traded as high as $1.75 and last traded at $1.74. 320,070 shares were traded during mid-day trading, a decline of 34% from the average session volume of 486,688 shares. The stock had previously closed at $1.64.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELYM.
No results
No recent SID articles mention ELYM.
